Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Anemia

ClinicalTrials.gov lists 4,659 trials for Anemia or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 124.

MeSH D000740 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 413 Phase 1/2 Phase 1/2 233 Phase 2 Phase 2 868 Phase 2/3 Phase 2/3 84 Phase 3 Phase 3 630 Phase 4 Phase 4 383 Not applicable Not applicable 983 Observational Observational 1,045 Phase 1 Phase 1 413 Phase 1/2 Phase 1/2 233 Phase 2 Phase 2 868 Phase 2/3 Phase 2/3 84 Phase 3 Phase 3 630 Phase 4 Phase 4 383 Not applicable Not applicable 983 Observational Observational 1,045

Trials per phase

2 more sections with rows

1,663 of the 4,659 trials are tagged with Anemia itself; the rest are tagged with a narrower condition beneath it.

Get the Anemia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Anemia trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 234

1990: 3 trials (Observational 2, Phase 2 1) 1991: 2 trials (Not applicable 1, Phase 2 1) 1992: 5 trials (Not applicable 2, Phase 3 1, Phase 2 2) 1993: 11 trials (Observational 3, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 3) 1994: 5 trials (Phase 3 1, Phase 2 4) 1995: 9 trials (Observational 2, Not applicable 3, Phase 3 2, Phase 2/3 1, Phase 2 1) 1996: 17 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 5, Phase 1 3) 1997: 14 trials (Not applicable 3, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1 1) 1998: 34 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 14, Phase 1/2 2, Phase 1 6) 1999: 39 trials (Observational 4, Not applicable 3, Phase 4 3, Phase 3 3, Phase 2 15, Phase 1/2 5, Phase 1 6) 2000: 56 trials (Observational 3, Not applicable 7, Phase 4 2, Phase 3 10, Phase 2/3 2, Phase 2 15, Phase 1/2 6, Phase 1 11) 2001: 52 trials (Observational 7, Not applicable 5, Phase 4 2, Phase 3 6, Phase 2 24, Phase 1/2 4, Phase 1 4) 2002: 79 trials (Observational 5, Not applicable 9, Phase 4 14, Phase 3 16, Phase 2/3 3, Phase 2 21, Phase 1/2 6, Phase 1 5) 2003: 87 trials (Observational 9, Not applicable 13, Phase 4 14, Phase 3 15, Phase 2/3 2, Phase 2 27, Phase 1/2 2, Phase 1 5) 2004: 121 trials (Observational 14, Not applicable 8, Phase 4 12, Phase 3 39, Phase 2 31, Phase 1/2 5, Phase 1 12) 2005: 126 trials (Observational 15, Not applicable 18, Phase 4 10, Phase 3 29, Phase 2/3 1, Phase 2 36, Phase 1/2 3, Phase 1 14) 2006: 128 trials (Other 1, Observational 26, Not applicable 8, Phase 4 7, Phase 3 25, Phase 2/3 6, Phase 2 35, Phase 1/2 7, Phase 1 13) 2007: 136 trials (Observational 26, Not applicable 21, Phase 4 12, Phase 3 30, Phase 2/3 2, Phase 2 25, Phase 1/2 8, Phase 1 12) 2008: 135 trials (Observational 32, Not applicable 18, Phase 4 12, Phase 3 30, Phase 2/3 3, Phase 2 22, Phase 1/2 10, Phase 1 8) 2009: 144 trials (Observational 34, Not applicable 26, Phase 4 11, Phase 3 17, Phase 2/3 5, Phase 2 31, Phase 1/2 12, Phase 1 8) 2010: 153 trials (Observational 35, Not applicable 38, Phase 4 14, Phase 3 15, Phase 2/3 2, Phase 2 30, Phase 1/2 5, Phase 1 14) 2011: 147 trials (Other 1, Observational 35, Not applicable 24, Phase 4 16, Phase 3 16, Phase 2/3 1, Phase 2 28, Phase 1/2 9, Phase 1 17) 2012: 158 trials (Observational 40, Not applicable 32, Phase 4 10, Phase 3 12, Phase 2/3 5, Phase 2 36, Phase 1/2 7, Phase 1 16) 2013: 155 trials (Observational 35, Not applicable 33, Phase 4 18, Phase 3 13, Phase 2 30, Phase 1/2 11, Phase 1 15) 2014: 192 trials (Observational 42, Not applicable 42, Phase 4 12, Phase 3 17, Phase 2/3 5, Phase 2 41, Phase 1/2 13, Phase 1 20) 2015: 164 trials (Observational 28, Not applicable 43, Phase 4 17, Phase 3 20, Phase 2/3 3, Phase 2 24, Phase 1/2 7, Phase 1 22) 2016: 190 trials (Other 1, Observational 42, Not applicable 50, Phase 4 16, Phase 3 36, Phase 2/3 2, Phase 2 24, Phase 1/2 9, Phase 1 10) 2017: 215 trials (Observational 50, Not applicable 40, Phase 4 21, Phase 3 29, Phase 2/3 2, Phase 2 42, Phase 1/2 11, Phase 1 20) 2018: 233 trials (Observational 50, Not applicable 67, Phase 4 17, Phase 3 32, Phase 2/3 7, Phase 2 36, Phase 1/2 8, Phase 1 16) 2019: 218 trials (Observational 57, Not applicable 53, Phase 4 17, Phase 3 32, Phase 2/3 6, Phase 2 31, Phase 1/2 9, Phase 1 13) 2020: 194 trials (Observational 54, Not applicable 43, Phase 4 19, Phase 3 23, Phase 2/3 4, Phase 2 25, Phase 1/2 7, Phase 1 19) 2021: 226 trials (Observational 76, Not applicable 55, Phase 4 18, Phase 3 25, Phase 2/3 3, Phase 2 32, Phase 1/2 6, Phase 1 11) 2022: 226 trials (Observational 71, Not applicable 63, Phase 4 10, Phase 3 24, Phase 2/3 5, Phase 2 33, Phase 1/2 8, Phase 1 12) 2023: 216 trials (Observational 60, Not applicable 54, Phase 4 19, Phase 3 19, Phase 2/3 5, Phase 2 31, Phase 1/2 8, Phase 1 20) 2024: 234 trials (Observational 72, Not applicable 66, Phase 4 18, Phase 3 15, Phase 2/3 2, Phase 2 24, Phase 1/2 12, Phase 1 25) 2025: 231 trials (Observational 53, Not applicable 59, Phase 4 15, Phase 3 29, Phase 2/3 2, Phase 2 28, Phase 1/2 15, Phase 1 30)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 218
2025 231
2024 234
2023 216
2022 226
2021 226
2020 194
2019 218
2018 233
2017 215

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 240 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 347 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 2,954 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Anemia trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 413
Phase 1/2 233
Phase 2 868
Phase 2/3 84
Phase 3 630
Phase 4 383
Not applicable 983
Observational 1,045
Expanded access 19
Unknown 1

How many Anemia trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 202
Recruiting 471
Enrolling by invitation 28
Active, not recruiting 184
Available 8

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Anemia trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 124
Hoffmann-La Roche 105
Novartis Pharmaceuticals 83
Amgen 65
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 60

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Anemia? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EPOETIN ALFA 194
Cytoxan 155
Fer-In-Sol 104
Busulfan 79

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 172
darbepoetin alfa SF 111
Cyclosporine 0.05% 104
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] 94
Total Body Irradiation 85

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Anemia trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 3,251 232
End stage renal disease 2,082 25
Cardiac failure congestive 1,768 91
Anaemia 1,484 160
Sepsis 1,429 210

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Anemia? (1,822)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Hemoglobin and Perihematomal Edema After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Neurocritical care 2026 Yes
Effectiveness of Closed Blood-Sampling Devices in Critically Ill Adults: A Feasibility Trial. Nursing in critical care 2026 Yes
Transfusion thresholds and other strategies for guiding red blood cell transfusion. The Cochrane database of systematic reviews 2025 Yes
Best practices for iatrogenic anaemia prevention in the intensive care unit: Blood-sparing techniques. Nursing in critical care 2025 Yes
Is noninvasive hemoglobin measurement suitable for children undergoing preoperative anesthesia consultation? Journal of clinical monitoring and computing 2025 Yes

Showing 5 of 1,822 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages